Developer docs
API playgroundTry for free, no card

Search company profiles

IncellDx

Full company profile

uuid0002rju

Namestring
IncellDx
Legal namestring
IncellDx, Inc.
Websiteurl
incelldx.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

IncellDx, Inc. is a privately held, Delaware-incorporated molecular diagnostics company founded in 2009 and headquartered in Hayward, California, with a secondary office in Traverse City, Michigan. The company develops single-cell diagnostic products based on a proprietary platform that combines multiplex RNA in situ hybridization, multiplex protein detection, and DNA/cell cycle analysis to enable simultaneous classification and biomarker profiling at the individual cell level. The catalog spans HPV E6/E7 mRNA probes and the CE-IVD HPV OncoTect 3Dx cervical cancer screening kit, CMV mRNA probes, the incellPREP tissue single-cell suspension system (IVD/CE-IVD), the BioINK PD-L1 CTC circulating tumor cell research kit, and a line of general laboratory reagents and antibodies (incellMAX, CytoStat triCHROME, anti-PD-L1, anti-CD45, anti-pan cytokeratin) distributed across RUO, GPR, ASR, CE-IVD, and US-IVD regulatory designations.

The company sells primarily on a B2B basis to clinical laboratories, physicians, and research institutions via direct sales and the HealthBio e-commerce platform, with electronic instruction-for-use delivery through a key-code system at eifu.incelldx.com. ISO 13485:2016 certification (SGS) underpins manufacturing quality, and disclosed funding to date totals approximately $9.5 million across 2010 and 2012 rounds plus an in-progress $13.5 million exempt offering filed in July 2024. Leadership comprises CEO Bruce Patterson, founder and VP of Marketing Carol Penfold-Patterson, Chief Business Officer Chris Meda, and Chief Operating Officer Todd Pollard. The company is too small to have disclosed revenue, named anchor customers, or M&A activity, and AI/ML capabilities are not part of its stated technology stack.

Short descriptiontext

IncellDx is a private molecular diagnostics company developing single-cell IVD and research-use products—including the CE-IVD HPV OncoTect 3Dx kit and the incellPREP sample-prep system—sold B2B to clinical laboratories, physicians, and research institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
single cell diagnostics, molecular diagnostics reagents, in vitro diagnostics, HPV E6 E7 mRNA, circulating tumor cell analysis
Industry4 codes
1IVD Reagents, Assay Kits & Consumables (Non-instrument)
CodeHLAHAAAMPrimaryYes
2Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
CodeHLAAALAEPrimaryNo
3Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
CodeHLAGAIAIPrimaryNo
4Companion Diagnostics (CDx) & Precision Medicine IVD
CodeHLAHAAAJPrimaryNo
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
Molecular Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Products and Reagents
TypeOne Time License
Description

Sale of IVD/CE-IVD diagnostic products including HPV OncoTect 3Dx, incellPREP sample preparation systems, and various reagents. Products are sold to medical laboratories and healthcare providers with regulatory clearances (CE-IVD, US-IVD) for clinical use.

healthbio.com
2Research Use Only (RUO) Products
TypeOne Time License
Description

Sale of research reagents including HPV Control Cells, CMV mRNA Probe, and BioINK products for laboratory research applications.

healthbio.com
3General Purpose Reagents (GPR) and ASR Products
TypeOne Time License
Description

Sale of hybridization core reagents, cell cycle dyes, fixatives, and antibodies to clinical and research laboratories.

healthbio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1incellPREP
Description

Sample preparation system for tissue single cell suspension, including homogenizers, sample racks, and battery packs

healthbio.com
+4 more records
Core offering1 text field

IncellDx manufactures and sells single cell diagnostic products and reagents, including IVD/CE-IVD kits (HPV OncoTect 3Dx, incellPREP tissue single cell suspension system), probes (HPV E6/E7 mRNA, CMV mRNA), general laboratory reagents (incellMAX fixatives, Hybridization Core Reagents, Cell Cycle Dye, CytoStat triCHROME), and antibodies (Anti PD-L1, Anti CD45, Anti Pan Cytokeratin). Products serve clinical laboratories, research institutions, and physicians with regulatory designations spanning RUO, GPR, ASR, CE-IVD, and US-IVD, enabling precision medicine diagnostics in oncology (HPV, CTCs) and infectious disease (CMV).

Differentiator
Functional benefit
Problem solved
Product overview1 text field

IncellDx is a single cell diagnostic company offering a comprehensive portfolio of diagnostic products and reagents based on its proprietary multiplex RNA in situ hybridization and multiplex protein detection technology platform. The product portfolio includes: (1) Probes and assays including HPV E6, E7 mRNA Probe, CMV mRNA Probe, and HPV OncoTect 3Dx for cervical cancer diagnostics; (2) Laboratory reagents including Hybridization Core Reagents, incellMAX fixatives, Cell Cycle Dye, and CytoStat triCHROME for cell analysis; (3) Antibodies including Anti PD-L1, Anti CD45, and Anti Pan Cytokeratin; (4) The incellPREP sample preparation system comprising homogenizers, sample racks, and battery packs for tissue processing; and (5) BioINK PD-L1 CTC Core Kit for circulating tumor cell research. Products carry various regulatory designations including RUO (Research Use Only), GPR (General Purpose Reagent), ASR (Analyte Specific Reagent), IVD/CE-IVD, and US-IVD. The company positions itself in the precision medicine space enabling simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers.

Product and service14 records
1HPV OncoTect 3Dx
CategoryDiagnostic kit (cervical cancer screening)
Description

CE-IVD certified kit for HPV E6, E7 mRNA detection using the OncoTect platform, used for cervical cancer screening. Available in limited geographies, not available in US and China.

2HPV E6, E7 mRNA Probe
CategoryDiagnostic probe
Description

Ready-to-Use probe for detecting HPV E6 and E7 mRNA expression, used in cervical cancer screening and diagnostics. Regulated as Analyte Specific Reagent (ASR).

3CMV mRNA Probe
CategoryDiagnostic probe
Description

CMV mRNA Probe for detection of Cytomegalovirus mRNA expression in cells. Regulated for Research Use Only (RUO).

4incellPREP Tissue Single Cell Suspension System
CategorySample preparation device (IVD/CE-IVD)
Description

IVD/CE-IVD certified homogenizer system for preparing single cell suspensions from tissue samples for downstream analysis, including sample rack and battery pack components.

5BioINK PD-L1 CTC Core Kit
CategoryResearch kit (RUO)
Description

Research use only kit for detecting PD-L1 expression on circulating tumor cells (CTCs) for cancer research applications.

6Hybridization Core Reagents
CategoryLaboratory reagent (GPR)
Description

Core reagents for in situ hybridization procedures, sold as bulk format for general laboratory use. Regulated as General Purpose Reagent (GPR).

7HPV Control Cells
CategoryControl reagent (RUO)
Description

Control cells for HPV testing validation and quality control in laboratory settings. Regulated for Research Use Only (RUO).

8incellMAX
CategoryLaboratory reagent (GPR)
Description

Fix/Permeabilizer reagent for cell fixation and permeabilization, enabling intracellular staining for single cell analysis. Regulated as General Purpose Reagent (GPR).

9incellMAX C
CategoryLaboratory reagent (GPR)
Description

Fixative reagent for preserving cell samples prior to analysis. Regulated as General Purpose Reagent (GPR).

10Cell Cycle Dye
CategoryLaboratory reagent (GPR)
Description

Reagent for cell cycle analysis and DNA content measurement. Regulated as General Purpose Reagent (GPR).

11CytoStat triCHROME
CategoryDiagnostic reagent (IVD/CE-IVD)
Description

CE-IVD certified reagent kit for multi-color cell analysis and diagnostics.

12Anti PD-L1 Antibody
CategoryAntibody reagent (ASR)
Description

Antibody for PD-L1 detection, used in cancer immunotherapy assessment and diagnostics. Regulated as Analyte Specific Reagent (ASR).

13Anti CD45 Antibody
CategoryAntibody reagent (ASR)
Description

Antibody for CD45 (leukocyte common antigen) detection used in cell identification and hematological diagnostics. Regulated as Analyte Specific Reagent (ASR).

14Anti Pan Cytokeratin
CategoryAntibody reagent (ASR)
Description

Antibody for pan-cytokeratin detection used in epithelial cell identification and cancer diagnostics. Regulated as Analyte Specific Reagent (ASR).

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Spatial biology and single cell analysis company (GeoMx, CosMx, nCounter). Comparable to IncellDx in multiplexed RNA in situ hybridization and oncology biomarker profiling, with overlapping research customer base.

TypeBroad incumbent
Description

Major women's health diagnostics company with a leading HPV testing portfolio (Aptima). Comparable to IncellDx because it operates in the HPV molecular diagnostics and cervical cancer screening market, the same clinical use case targeted by HPV OncoTect 3Dx.

TypeBroad incumbent
Description

Global IVD and HPV diagnostics leader (cobas HPV test) and a major player in tissue-based companion diagnostics. Directly comparable to IncellDx in HPV cervical cancer screening and oncology IVD, with substantially broader scale and regulatory footprint.

TypeBroad incumbent
Description

Global molecular diagnostics and sample preparation company with HPV tests and the QIAsymphony automation platform. Comparable to IncellDx because of its HPV testing franchise and its sample-prep consumables business, which overlaps with incellPREP.

TypeBroad incumbent
Description

Large diagnostics and life sciences company with BD Onclarity HPV assay and significant flow cytometry and single cell analysis capabilities. Comparable to IncellDx in HPV diagnostics and in multiplexed single cell analysis workflows.

TypeDirect peer
Description

Single cell genomics and multi-omics platform company offering Chromium single cell assays and Visium spatial products. Closely comparable to IncellDx because both sell single cell analysis solutions to research and clinical lab customers, though 10x is instrument-platform-led.

TypeDirect peer
Description

Life science reagents and diagnostics company with RNAscope in situ hybridization products and protein biology reagents. Directly comparable to IncellDx because of overlapping multiplex RNA ISH technology and shared research and clinical lab customers.

TypeBroad incumbent
Description

Major IVD player with HPV and infectious disease molecular tests. Comparable to IncellDx in the HPV and infectious disease molecular diagnostics market, particularly for HPV cervical screening and CMV testing.

TypeBroad incumbent
Description

Molecular diagnostics company with the GeneXpert platform offering HPV, CMV, and other infectious disease tests. Comparable to IncellDx in clinical molecular diagnostics for HPV and CMV, with much broader installed instrument base.

TypeEmerging player
Description

Specialized single cell and circulating tumor cell analysis company. Comparable to IncellDx because both focus on single cell and CTC workflows, with overlapping oncology research and translational customer segments.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IncellDx

Molecular Diagnosticsincelldx.com

IncellDx is a private molecular diagnostics company developing single-cell IVD and research-use products—including the CE-IVD HPV OncoTect 3Dx kit and the incellPREP sample-prep system—sold B2B to clinical laboratories, physicians, and research institutions.

What IncellDx does

IncellDx, Inc. is a privately held, Delaware-incorporated molecular diagnostics company founded in 2009 and headquartered in Hayward, California, with a secondary office in Traverse City, Michigan. The company develops single-cell diagnostic products based on a proprietary platform that combines multiplex RNA in situ hybridization, multiplex protein detection, and DNA/cell cycle analysis to enable simultaneous classification and biomarker profiling at the individual cell level. The catalog spans HPV E6/E7 mRNA probes and the CE-IVD HPV OncoTect 3Dx cervical cancer screening kit, CMV mRNA probes, the incellPREP tissue single-cell suspension system (IVD/CE-IVD), the BioINK PD-L1 CTC circulating tumor cell research kit, and a line of general laboratory reagents and antibodies (incellMAX, CytoStat triCHROME, anti-PD-L1, anti-CD45, anti-pan cytokeratin) distributed across RUO, GPR, ASR, CE-IVD, and US-IVD regulatory designations.

The company sells primarily on a B2B basis to clinical laboratories, physicians, and research institutions via direct sales and the HealthBio e-commerce platform, with electronic instruction-for-use delivery through a key-code system at eifu.incelldx.com. ISO 13485:2016 certification (SGS) underpins manufacturing quality, and disclosed funding to date totals approximately $9.5 million across 2010 and 2012 rounds plus an in-progress $13.5 million exempt offering filed in July 2024. Leadership comprises CEO Bruce Patterson, founder and VP of Marketing Carol Penfold-Patterson, Chief Business Officer Chris Meda, and Chief Operating Officer Todd Pollard. The company is too small to have disclosed revenue, named anchor customers, or M&A activity, and AI/ML capabilities are not part of its stated technology stack.

IncellDx firmographics

Firmographics
Name
IncellDx
Legal name
IncellDx, Inc.
Website
https://incelldx.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
IncellDx is a private molecular diagnostics company developing single-cell IVD and research-use products—including the CE-IVD HPV OncoTect 3Dx kit and the incellPREP sample-prep system—sold B2B to clinical laboratories, physicians, and research institutions.
Ownership category
akta.pro rank

IncellDx industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Surgical and Medical Instrument Manufacturing (339112)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)
akta.pro secondary industries
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Companion Diagnostics (CDx) & Precision Medicine IVD (HLAHAAAJ)

Keywords

  • Single cell diagnostics
  • Molecular diagnostics reagents
  • In vitro diagnostics
  • HPV E6 E7 mRNA
  • Circulating tumor cell analysis

Where IncellDx is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices2 records

Markets served

IncellDx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Products and Reagents: Sale of IVD/CE-IVD diagnostic products including HPV OncoTect 3Dx, incellPREP sample preparation systems, and various reagents. Products are sold to medical laboratories and healthcare providers with regulatory clearances (CE-IVD, US-IVD) for clinical use.
  2. Research Use Only (RUO) Products: Sale of research reagents including HPV Control Cells, CMV mRNA Probe, and BioINK products for laboratory research applications.
  3. General Purpose Reagents (GPR) and ASR Products: Sale of hybridization core reagents, cell cycle dyes, fixatives, and antibodies to clinical and research laboratories.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

IncellDx product offering

Product offering

Core offering

IncellDx manufactures and sells single cell diagnostic products and reagents, including IVD/CE-IVD kits (HPV OncoTect 3Dx, incellPREP tissue single cell suspension system), probes (HPV E6/E7 mRNA, CMV mRNA), general laboratory reagents (incellMAX fixatives, Hybridization Core Reagents, Cell Cycle Dye, CytoStat triCHROME), and antibodies (Anti PD-L1, Anti CD45, Anti Pan Cytokeratin). Products serve clinical laboratories, research institutions, and physicians with regulatory designations spanning RUO, GPR, ASR, CE-IVD, and US-IVD, enabling precision medicine diagnostics in oncology (HPV, CTCs) and infectious disease (CMV).

Product overview

IncellDx is a single cell diagnostic company offering a comprehensive portfolio of diagnostic products and reagents based on its proprietary multiplex RNA in situ hybridization and multiplex protein detection technology platform. The product portfolio includes: (1) Probes and assays including HPV E6, E7 mRNA Probe, CMV mRNA Probe, and HPV OncoTect 3Dx for cervical cancer diagnostics; (2) Laboratory reagents including Hybridization Core Reagents, incellMAX fixatives, Cell Cycle Dye, and CytoStat triCHROME for cell analysis; (3) Antibodies including Anti PD-L1, Anti CD45, and Anti Pan Cytokeratin; (4) The incellPREP sample preparation system comprising homogenizers, sample racks, and battery packs for tissue processing; and (5) BioINK PD-L1 CTC Core Kit for circulating tumor cell research. Products carry various regulatory designations including RUO (Research Use Only), GPR (General Purpose Reagent), ASR (Analyte Specific Reagent), IVD/CE-IVD, and US-IVD. The company positions itself in the precision medicine space enabling simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers.

Differentiator

Problem solved

Functional benefit

Brands

  • incellPREP: Sample preparation system for tissue single cell suspension, including homogenizers, sample racks, and battery packs
  • incellMAX
  • BioINK
  • HPV OncoTect 3Dx
  • CytoStat triCHROME

Products and services

  • HPV OncoTect 3Dx CE-IVD certified kit for HPV E6, E7 mRNA detection using the OncoTect platform, used for cervical cancer screening. Available in limited geographies, not available in US and China.
  • HPV E6, E7 mRNA Probe Ready-to-Use probe for detecting HPV E6 and E7 mRNA expression, used in cervical cancer screening and diagnostics. Regulated as Analyte Specific Reagent (ASR).
  • CMV mRNA Probe CMV mRNA Probe for detection of Cytomegalovirus mRNA expression in cells. Regulated for Research Use Only (RUO).
  • incellPREP Tissue Single Cell Suspension System IVD/CE-IVD certified homogenizer system for preparing single cell suspensions from tissue samples for downstream analysis, including sample rack and battery pack components.
  • BioINK PD-L1 CTC Core Kit Research use only kit for detecting PD-L1 expression on circulating tumor cells (CTCs) for cancer research applications.
  • Hybridization Core Reagents Core reagents for in situ hybridization procedures, sold as bulk format for general laboratory use. Regulated as General Purpose Reagent (GPR).
  • HPV Control Cells Control cells for HPV testing validation and quality control in laboratory settings. Regulated for Research Use Only (RUO).
  • incellMAX Fix/Permeabilizer reagent for cell fixation and permeabilization, enabling intracellular staining for single cell analysis. Regulated as General Purpose Reagent (GPR).
  • incellMAX C Fixative reagent for preserving cell samples prior to analysis. Regulated as General Purpose Reagent (GPR).
  • Cell Cycle Dye Reagent for cell cycle analysis and DNA content measurement. Regulated as General Purpose Reagent (GPR).
  • CytoStat triCHROME CE-IVD certified reagent kit for multi-color cell analysis and diagnostics.
  • Anti PD-L1 Antibody Antibody for PD-L1 detection, used in cancer immunotherapy assessment and diagnostics. Regulated as Analyte Specific Reagent (ASR).
  • Anti CD45 Antibody Antibody for CD45 (leukocyte common antigen) detection used in cell identification and hematological diagnostics. Regulated as Analyte Specific Reagent (ASR).
  • Anti Pan Cytokeratin Antibody for pan-cytokeratin detection used in epithelial cell identification and cancer diagnostics. Regulated as Analyte Specific Reagent (ASR).

Companies that use IncellDx

Customer profile

Segments3 records

Ideal customer profiles3 records

IncellDx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

IncellDx partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

IncellDx competitors and assessment

Company assessment

Direct peers

  • NanoString Technologies: Spatial biology and single cell analysis company (GeoMx, CosMx, nCounter). Comparable to IncellDx in multiplexed RNA in situ hybridization and oncology biomarker profiling, with overlapping research customer base.
  • 10x Genomics: Single cell genomics and multi-omics platform company offering Chromium single cell assays and Visium spatial products. Closely comparable to IncellDx because both sell single cell analysis solutions to research and clinical lab customers, though 10x is instrument-platform-led.
  • Bio-Techne: Life science reagents and diagnostics company with RNAscope in situ hybridization products and protein biology reagents. Directly comparable to IncellDx because of overlapping multiplex RNA ISH technology and shared research and clinical lab customers.

Broad incumbents

  • Hologic: Major women's health diagnostics company with a leading HPV testing portfolio (Aptima). Comparable to IncellDx because it operates in the HPV molecular diagnostics and cervical cancer screening market, the same clinical use case targeted by HPV OncoTect 3Dx.
  • Roche Diagnostics: Global IVD and HPV diagnostics leader (cobas HPV test) and a major player in tissue-based companion diagnostics. Directly comparable to IncellDx in HPV cervical cancer screening and oncology IVD, with substantially broader scale and regulatory footprint.
  • Qiagen: Global molecular diagnostics and sample preparation company with HPV tests and the QIAsymphony automation platform. Comparable to IncellDx because of its HPV testing franchise and its sample-prep consumables business, which overlaps with incellPREP.
  • Becton Dickinson (BD): Large diagnostics and life sciences company with BD Onclarity HPV assay and significant flow cytometry and single cell analysis capabilities. Comparable to IncellDx in HPV diagnostics and in multiplexed single cell analysis workflows.
  • Abbott Diagnostics: Major IVD player with HPV and infectious disease molecular tests. Comparable to IncellDx in the HPV and infectious disease molecular diagnostics market, particularly for HPV cervical screening and CMV testing.
  • Cepheid (Danaher): Molecular diagnostics company with the GeneXpert platform offering HPV, CMV, and other infectious disease tests. Comparable to IncellDx in clinical molecular diagnostics for HPV and CMV, with much broader installed instrument base.

Emerging players

  • RareCyte: Specialized single cell and circulating tumor cell analysis company. Comparable to IncellDx because both focus on single cell and CTC workflows, with overlapping oncology research and translational customer segments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

IncellDx social profiles

Digital presence

IncellDx compliance and trust

Trust signal

Compliance1 record

IncellDx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IncellDx leadership team

Management profile

Number of profiles

Profiles4 records

IncellDx funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IncellDx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IncellDx

What does IncellDx do?

IncellDx manufactures and sells single cell diagnostic products and reagents, including IVD/CE-IVD kits (HPV OncoTect 3Dx, incellPREP tissue single cell suspension system), probes (HPV E6/E7 mRNA, CMV mRNA), general laboratory reagents (incellMAX fixatives, Hybridization Core Reagents, Cell Cycle Dye, CytoStat triCHROME), and antibodies (Anti PD-L1, Anti CD45, Anti Pan Cytokeratin). Products serve clinical laboratories, research institutions, and physicians with regulatory designations spanning RUO, GPR, ASR, CE-IVD, and US-IVD, enabling precision medicine diagnostics in oncology (HPV, CTCs) and infectious disease (CMV).

Is IncellDx a public or private company?

IncellDx is a private company. It is classified as unknown and is currently operating.

When was IncellDx founded?

IncellDx was founded in 2009. It employs 11 to 50 people.

Where is IncellDx based?

IncellDx is headquartered in Menlo Park, United States, in the North America region.

How does IncellDx make money?

Three revenue lines are on record. Diagnostic Products and Reagents are the primary driver. The others are research Use Only (RUO) Products and general Purpose Reagents (GPR) and ASR Products.

Who are IncellDx's main competitors?

Direct peers on record are NanoString Technologies, 10x Genomics and Bio-Techne. Broad incumbents are Hologic, Roche Diagnostics, Qiagen, Becton Dickinson (BD), Abbott Diagnostics and Cepheid (Danaher). RareCyte is listed as an emerging player.

Does IncellDx have an API?

No public API is recorded for IncellDx.

What industry is IncellDx in?

IncellDx's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DInCellDx, Inc. filed a Form D with the SEC on July 23, 2024, announcing an exempt securities offering under Rule 506(b) that commenced on July 16, 2024. The company is raising up to $13.5 million in equity capital, with $500,000 already sold to one investor.PR NewswirePeploBio and IncellDX Partner to Launch the First Long COVID Test in the UK and EUPeploBio and IncellDX have partnered to launch the first laboratory developed test in the UK and EU designed to diagnose Long COVID, using the incellKINE Long Hauler Index technology to identify a distinctive immunologic profile unique to Long COVID patients. The test aims to help physicians differentiate Long COVID from other conditions with similar symptoms such as Lyme disease and ME-CFS, addressing a critical diagnostic gap for a condition affecting more than 65 million people worldwide. PeploBio, an ISO 15189 accredited clinical laboratory based in Guildford, England, is leading the commercial launch in collaboration with IncellDX, a precision medicine company headquartered in Hayward, California.Respiratory TherapyLong COVID Diagnostic Test Launches in AustraliaA diagnostic test for long COVID has been launched and is now available to patients across Australia, developed by IGeneX using IncellDx's machine learning-based incellKINE assay technology. The blood-based test assesses distinctive immunologic profiles through cytokine and chemokine biomarkers, achieving 97% sensitivity, and Healius Pathology is facilitating sample collections at 22 collection centers nationwide. The test received CE-IVD marking in Europe in 2022, enabling its commercial deployment.The Guardian‘What do I have to lose?’: desperate long Covid patients turn to ‘miracle cures’Long Covid patients in the US, facing prolonged symptoms and months-long wait times at specialized clinics, are spending thousands of dollars on unproven alternative therapies and supplements with no scientific backing. The complementary and alternative medicine industry is expected to quadruple over the next seven years, driven partly by demand for alternative Covid treatments. Companies like IncellDX are offering unproven diagnostic tests and treatment protocols at high cost, with the company's founder promoting these approaches through social media while declining to conduct clinical trials.PR NewswireIncellDx Files Patent for COVID Long Hauler Index and Active COVID-19 Severity ScoreIncellDx, a precision medicine diagnostics company based in San Carlos, California, has filed patents for two machine learning algorithms designed to identify COVID long haulers and generate COVID-19 severity scores using a tailored cytokine and chemokine immune panel. The algorithms were developed from analysis of hundreds of COVID-19 patients spanning mild to critical disease severity, with research suggesting up to 80% of infected individuals may experience long-term symptoms. The company, in collaboration with Drs. Ram Yogendra and Purvi Parikh, also launched covidlonghaulers.com on January 29, 2021, as a resource for patients and clinicians dealing with post-COVID complications.PR NewswireIncellDx to Study Maraviroc, a CCR5 antagonist, in a COVID-19 Phase 2 Clinical TrialIncellDx announced a collaboration on Phase 2 clinical trial NCT04435522 to study Pfizer's FDA-approved CCR5 antagonist Maraviroc as a treatment for hospitalized COVID-19 patients. The trial will evaluate whether a seven-day treatment at the approved HIV dosage is safe and tolerable, with IncellDx conducting CCR5 receptor occupancy assays, cytokine storm quantification, and viral load measurements. Early company data suggests CCR5 antagonism may restore immune homeostasis and reduce SARS-CoV-2 plasma viral load.PR NewswireIncellDx and MD Biosciences Sign Definitive Agreement for Commercialization of COVID-19/Cytokine Storm Cytokine Panel and CCR5 Receptor Occupancy in US and EUIncellDx, Inc. announced on September 15, 2020 the signing of a definitive agreement with MD Biosciences, Inc. for the commercialization of novel diagnostic assays targeting COVID-19 and cytokine storm conditions. MD Biosciences will validate and commercially offer these lab tests, measuring cytokine levels and CCR5 receptor occupancy, in the U.S. and European Union to aid in diagnosing and managing COVID-19 patients experiencing prolonged symptoms, known as "long-haulers." The partnership also includes plans to establish a COVID-19 long-hauler diagnosis and treatment initiative ahead of anticipated cytokine storm-related therapeutic approvals.PR NewswireFactorial Diagnostics, IncellDx Sign Exclusive License for Novel in situ Library Prep for Subsequent Next Generation DNA SequencingFactorial Diagnostics and IncellDx have entered into an exclusive license and supply agreement for the IncellMax-Seq reagent technology, enabling the development of a multi-omic cancer diagnostic workflow. The technology addresses a limitation of current bulk NGS-based cancer tests by preserving critical phenotypic information during library preparation that is typically lost in conventional methods. The collaboration aims to increase clinical sensitivity and enable more precise therapeutic approaches in cancer diagnostics, though specific financial terms of the agreement were not disclosed.GlobeNewswireCytoDyn to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19CytoDyn announced it is offering exploratory cytokine profiling through IncellDx to help physicians understand the pathogenesis of childhood inflammatory disease related to COVID-19. The tests are not for clinical decision making, and the company hopes they will support its CCR5 antagonist leronlimab as a potential treatment.GlobeNewswireCytoDyn Executes Exclusive Worldwide Licensing Agreement with IncellDX for PA-14 and PRO 140 for Diagnostic Testing PurposesCytoDyn executed an exclusive worldwide licensing agreement with IncellDX to sell non-commercial grade PA-14 or PRO 140 for immunoassays measuring CCR5 levels. IncellDX will handle assay development, regulatory clearance, and commercialization at its expense, with monthly demand forecasts. The deal is expected to generate CytoDyn's first revenues over the next several months.